You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZuclopenthixol
Accession NumberDB01624  (DB08919, DB08920)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionZuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.
Structure
Thumb
Synonyms
cis-Clopenthixol
Zuclopenthixolum
Zuclopentixol
External Identifiers
  • N05AF05
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopixol - Tab 10mgTablet10 mgOralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol - Tab 25mgTablet25 mgOralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol - Tab 40mgTablet40 mgOralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Acuphase - Liq Im 50mg/mlLiquid50 mgIntramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 200mg/mlLiquid200 mgIntramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 500mg/mlLiquid500 mgIntramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot 200mg/mlSolution200 mgIntramuscularLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Depot 500mg/mlLiquid500 mgIntramuscularLundbeck Canada IncNot applicableNot applicableCanada
Clopixol Tablets 10mgTablet10 mgOralLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Tablets 25mgTablet25 mgOralLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Tablets 40mgTablet40 mgOralLundbeck Canada Inc1997-05-022003-03-24Canada
Clopixol-acuphase 50mg/mlSolution50 mgIntramuscularLundbeck Canada Inc1997-05-02Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcuphaseH. Lundbeck A/S
Ciatyl-ZBayer Vital
CisordinolH. Lundbeck A/S
ClopixolH. Lundbeck A/S
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Zuclopenthixol acetate
85721-05-7
Thumb
  • InChI Key: OXAUOBQMCDIVPQ-IOXNKQMXSA-N
  • Monoisotopic Mass: 442.148176515
  • Average Mass: 443.001
DBSALT000545
Zuclopenthixol decanoate
64053-00-5
Thumb
  • InChI Key: QRUAPADZILXULG-WKIKZPBSSA-N
  • Monoisotopic Mass: 554.273377027
  • Average Mass: 555.214
DBSALT000787
Zuclopenthixol dihydrochloride
58045-23-1
Thumb
  • InChI Key: LPWNZMIBFHMYMX-MHKBYHAFSA-N
  • Monoisotopic Mass: 472.090967307
  • Average Mass: 473.887
DBSALT000546
Categories
UNII47ISU063SG
CAS number53772-83-1
WeightAverage: 400.965
Monoisotopic: 400.137611829
Chemical FormulaC22H25ClN2OS
InChI KeyWFPIAZLQTJBIFN-DVZOWYKESA-N
InChI
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Pharmacology
IndicationUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
Structured Indications
PharmacodynamicsZuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Mechanism of actionZuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
D(1B) dopamine receptorProteinyes
antagonist
HumanP21918 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Related Articles
AbsorptionUpon reaching the body water phase, the decanoate ester is slowly released from the oil depot, which is resultantly hydrolyzed to the active substance, zuclopenthixol. The decanoate ester provides a means of slow release since zuclopenthixol itself is a short-acting drug.
Volume of distribution

20 L/kg.

Protein binding98-99%
Metabolism

The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.

Route of eliminationPrimarily in the feces with approximately 10% in the urine.
Half life20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.
Clearance

approximately 0.9 L/min.

ToxicityAlthough there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia. Neuroleptic malignant syndrome may occur. Zuclopenthixol may potentiate anticholinergic effects of concurrent medications. Zuclopenthixol has a demonstrated antiemetic effect in animals, and may mask signs of toxicity due to other drug overdoses, or may mask symptoms of disease.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineZuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineZuclopenthixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zuclopenthixol.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zuclopenthixol.Approved
adipiplonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zuclopenthixol.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Zuclopenthixol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
AmiodaroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
AmperozideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amperozide.Experimental
AmphetamineZuclopenthixol may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideAnagrelide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
AprepitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
ArtemetherZuclopenthixol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Articaine.Approved
AsenapineZuclopenthixol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azaperone.Vet Approved
AzelastineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Zuclopenthixol.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
BenperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zuclopenthixol.Approved
BenzphetamineZuclopenthixol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Zuclopenthixol can be decreased when combined with Betaxolol.Approved
BoceprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.Approved, Illicit
BromocriptineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.Approved, Investigational
BuprenorphineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Zuclopenthixol can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Zuclopenthixol.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol.Approved
CarbamazepineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Zuclopenthixol.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zuclopenthixol.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zuclopenthixol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Zuclopenthixol.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zuclopenthixol.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorphenamine.Approved
ChlorphentermineZuclopenthixol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zuclopenthixol.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Zuclopenthixol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Zuclopenthixol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Zuclopenthixol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zuclopenthixol.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ClarithromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Zuclopenthixol can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clidinium.Approved
ClobazamThe metabolism of Zuclopenthixol can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.Approved, Illicit
ClotrimazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
CobicistatThe serum concentration of Zuclopenthixol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Zuclopenthixol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.Approved, Illicit
ConivaptanThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.Approved
CyclosporineThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zuclopenthixol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DelavirdineThe serum concentration of Zuclopenthixol can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zuclopenthixol.Approved, Vet Approved
DextroamphetamineZuclopenthixol may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zuclopenthixol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zuclopenthixol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Zuclopenthixol.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zuclopenthixol.Approved, Illicit, Vet Approved
DiethylpropionZuclopenthixol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.Approved, Illicit
DihydroergotamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zuclopenthixol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zuclopenthixol.Experimental, Illicit
DiltiazemThe serum concentration of Zuclopenthixol can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Doramectin.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
DoxycyclineThe serum concentration of Zuclopenthixol can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Illicit
DronedaroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Zuclopenthixol.Experimental, Illicit
DuloxetineThe metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Zuclopenthixol.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.Approved, Investigational
EliglustatZuclopenthixol may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zuclopenthixol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zuclopenthixol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
ErythromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zuclopenthixol.Approved
EthanolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zuclopenthixol.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zuclopenthixol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zuclopenthixol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Zuclopenthixol.Illicit, Vet Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zuclopenthixol.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zuclopenthixol.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zuclopenthixol.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
FosamprenavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Fosamprenavir.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Zuclopenthixol.Approved
FosphenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Zuclopenthixol.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Zuclopenthixol.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zuclopenthixol.Approved, Illicit
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Zuclopenthixol.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zuclopenthixol.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Zuclopenthixol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Zuclopenthixol.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zuclopenthixol.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
HydrocodoneZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.Approved, Illicit
Hydroxyamphetamine hydrobromideZuclopenthixol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IdelalisibThe serum concentration of Zuclopenthixol can be increased when it is combined with Idelalisib.Approved
IloperidoneZuclopenthixol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
IndinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe serum concentration of Zuclopenthixol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
IsoniazidThe metabolism of Zuclopenthixol can be decreased when combined with Isoniazid.Approved
IsradipineThe serum concentration of Zuclopenthixol can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zuclopenthixol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zuclopenthixol.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zuclopenthixol.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Zuclopenthixol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zuclopenthixol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zuclopenthixol.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Zuclopenthixol.Approved, Investigational
LisdexamfetamineZuclopenthixol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Zuclopenthixol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.Approved
LorcaserinThe metabolism of Zuclopenthixol can be decreased when combined with Lorcaserin.Approved
LovastatinThe serum concentration of Zuclopenthixol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zuclopenthixol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineZuclopenthixol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Zuclopenthixol.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melperone.Approved
MephedroneZuclopenthixol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineZuclopenthixol may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zuclopenthixol.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.Approved, Illicit
MequitazineZuclopenthixol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zuclopenthixol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Zuclopenthixol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Zuclopenthixol.Approved, Illicit
MethamphetamineZuclopenthixol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.Approved
MethotrimeprazineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zuclopenthixol.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zuclopenthixol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
MetoprololThe metabolism of Zuclopenthixol can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MetyrosineZuclopenthixol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Zuclopenthixol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MirtazapineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane.Approved
MMDAZuclopenthixol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Zuclopenthixol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.Approved, Investigational
NefazodoneThe serum concentration of Zuclopenthixol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
NilotinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
OlaparibThe serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved
OpiumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opium.Approved, Illicit
OrphenadrineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zuclopenthixol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zuclopenthixol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PanobinostatThe serum concentration of Zuclopenthixol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.Approved
Peginterferon alfa-2bThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.Approved, Vet Approved
PentobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
PerazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.Approved
PhenobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenoxyethanol.Approved
PhentermineZuclopenthixol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleZuclopenthixol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zuclopenthixol.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zuclopenthixol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zuclopenthixol.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PrimidoneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zuclopenthixol.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Propoxycaine.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
PSD502The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with PSD502.Investigational
PseudoephedrineZuclopenthixol may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.Approved, Illicit
QuetiapineQuetiapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Zuclopenthixol.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
QuinineQuinine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
RacloprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.Approved
RifabutinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ritanserin.Investigational
RitobegronZuclopenthixol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.Approved
RolapitantThe metabolism of Zuclopenthixol can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Romifidine.Vet Approved
RopiniroleZuclopenthixol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol.Approved
RotigotineZuclopenthixol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zuclopenthixol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SaquinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
SildenafilThe serum concentration of Zuclopenthixol can be increased when it is combined with Sildenafil.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
St. John's WortThe serum concentration of Zuclopenthixol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe metabolism of Zuclopenthixol can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved
SulfisoxazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Zuclopenthixol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
SuvorexantZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TandospironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zuclopenthixol.Approved
TelaprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TelithromycinThe serum concentration of Zuclopenthixol can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.Approved
TerbinafineThe metabolism of Zuclopenthixol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zuclopenthixol.Approved
TetracaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrodotoxin.Investigational
ThalidomideZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zuclopenthixol.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zuclopenthixol.Approved, Vet Approved
ThioridazineThioridazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiapride.Investigational
TiclopidineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zuclopenthixol.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zuclopenthixol.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zuclopenthixol.Approved, Investigational
VandetanibZuclopenthixol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Zuclopenthixol.Approved
VemurafenibZuclopenthixol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe serum concentration of Zuclopenthixol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Zuclopenthixol.Approved
VoriconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol.Approved, Investigational
ZolpidemZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zuclopenthixol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zotepine.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
  2. Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, Dubremetz JF: Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):179-83. doi: 10.1007/s00406-013-0413-4. Epub 2013 Jun 15. [PubMed:23771405 ]
  3. Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2012 Apr 18;4:CD000525. doi: 10.1002/14651858.CD000525.pub3. [PubMed:22513898 ]
  4. Nielsen MK, Johansen SS: Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2012 Sep;36(7):497-506. doi: 10.1093/jat/bks054. Epub 2012 Jun 19. [PubMed:22718540 ]
  5. Khalifa AE: Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45. [PubMed:15497819 ]
  6. Hood S, Orr K, Bennett L, Davies S: Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry. 2010 Apr;18(2):174-6. doi: 10.3109/10398560903473686. [PubMed:20175668 ]
  7. Link [Link]
  8. Link [Link]
External Links
ATC CodesN05AF05
AHFS Codes
  • 281608
PDB EntriesNot Available
FDA labelDownload (229 KB)
MSDSDownload (568 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9443
Blood Brain Barrier+0.9676
Caco-2 permeable-0.5313
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.8736
P-glycoprotein inhibitor IIInhibitor0.7439
Renal organic cation transporterInhibitor0.5829
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6722
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.7518
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8213
Ames testNon AMES toxic0.7617
CarcinogenicityNon-carcinogens0.9029
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.8877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6099
hERG inhibition (predictor II)Inhibitor0.7023
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral40 mg
LiquidIntramuscular50 mg
LiquidIntramuscular200 mg
LiquidIntramuscular500 mg
SolutionIntramuscular200 mg
TabletOral10 mg
TabletOral25 mg
SolutionIntramuscular50 mg
Prices
Unit descriptionCostUnit
Clopixol Acuphase 50 mg/ml16.52USD ml
Clopixol Depot 200 mg/ml16.52USD ml
Clopixol 25 mg Tablet1.06USD tablet
Clopixol 10 mg Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point~50http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
water solubilityslighthttp://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.46ALOGPS
logP4.22ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (140 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • N-alkylpiperazine
  • Chlorobenzene
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly : a review. Clin Drug Investig. 2003;23(5):287-322. [PubMed:17535043 ]
  2. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  3. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043 ]
  2. Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Dec;65(12):1229-35. doi: 10.1007/s00228-009-0696-6. [PubMed:19644682 ]
  3. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Link [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:18 / Updated on December 08, 2016 11:11